Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | bumetanide | 4595 | drug-path |
| Adherens junction | R-HSA-451386 | map04520 | bumetanide | 4595 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | bumetanide | 4595 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | bumetanide | 4595 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | bumetanide | 4595 | drug-path |
| Fc epsilon RI signaling pathway | R-HSA-2454202 | map04664 | bumetanide | 4595 | drug-path |
| VEGF signaling pathway | R-HSA-194138 | map04370 | bumetanide | 4595 | drug-path |
| GnRH signaling pathway | R-HSA-168638 | map04912 | bumetanide | 4595 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | sulfaquinoxaline | 108223 | drug-path |
| Shigellosis | 0 | map05131 | sulfaquinoxaline | 108223 | drug-path |
| Insulin signaling pathway | R-HSA-74752 | map04910 | sulfaquinoxaline | 108223 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | sulfaquinoxaline | 108223 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | sulfaquinoxaline | 108223 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | sulfaquinoxaline | 108223 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | L-methionine sulfoximine | 4915 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | L-methionine sulfoximine | 4915 | drug-path |
| TGF-beta signaling pathway | R-HSA-168638 | map04350 | L-methionine sulfoximine | 4915 | drug-path |
| Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | L-methionine sulfoximine | 4915 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | altretamine | 448537 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | altretamine | 448537 | drug-path |